Dr. Francesco Oddone, Head of the Glaucoma Research Unit at Bietti Foundation, Rome, speaks about the most interesting features of COMPASS, the unique automatic perimeter combined with a scanning ophthalmoscope, able to provide retinal threshold sensitivity as well as confocal images of the retina.
Eye-to-Eye Innovation Series
David Lin, MD, Medical Director Pacific Laser Eye Centre in Vancouver, Canada, shares his experiences with SCHWIND SmartSurfACE treatment and how this procedure completely transformed the way of the clinic performing laser surgery.
Prof. Michael Knorz, Founder & CEO, FreeVis LASIK Group, Germany, tells the reasons why he bought a new SCHWIND AMARIS laser system in 2017.
Dr. David Chang, M.D. describes his experience with ZEISS Cataract Suite markerless.
Giovanni Staurenghi, professor of Ophthalmology at the University of Milan speaks about OCT, infrared, and autofluorescence base images used in practice. He explains how using blu autofluorescence imaging speeds up flow in cleaning and helps in diagnosis.
Bruce Allan, MD, UK and David Kang, MD, South Korea, are SCHWIND users for many years. Both greatly appreciate the outstanding performance features offered by the SCHWIND AMARIS excimer laser technology. The company‘s spirit of innovation, their willingness to advance the art and science of refractive surgery, and their responsiveness to feedback. In this video, Dr. Allan and Dr. Kang comment on the sophisticated SCHWIND AMARIS features SmartPulse Technology and TransPRK.
Professor Rudy Nuijts, Professor James Wolffsohn, Dr Mark Cherny and Dr David Frazer share their views on the taboo topic of refractive surprise in cataract surgery. They explain what it means to have a refractive surprise, why they occur, the importance of patient satisfaction and the options available to surgeons (including Rayner Sulcoflex® case studies) when a situation involving a refractive surprise arises.
Professor Marc De Smet talks about the impact of Ozurdex in treating diabetic macular edema (DME) in the real world clinical setting. This renowned expert in the DME field, explores what the licensing of Ozurdex in DME means to both patients and retinal specialists when treating this potentially blinding condition.
Professor Anat Lowenstein talks about the impact of Ozurdex in treating diabetic macular edema (DME) in the real world clinical setting. This renowned expert in the DME field, explores what the licensing of Ozurdex in DME means to both patients and retinal specialists when treating this potentially blinding condition.
Professor Steve Arshinoff and Rayner CEO Tim Clover announce Rayner's recent acquisition of the Ophteis OVD range at the Company's celebratory event, held at the 2015 ESCRS in Barcelona.